Biopharmaceutical company discovering, developing, and commercializing innovative medicines in areas of unmet medical need.MoreShow less
Profile & Fundamentals
Gilead Sciences (GILD.NASDAQ) Profile & Fundamentals
Review Gilead Sciences reported earnings, valuation, balance sheet and ownership, with source tables and separate AI assessments.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Gilead Sciences: Company Profile & Ownership
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company profile record
Gilead Sciences Inc
Common Stock · Health Care · Biotechnology
Company
- Company / asset
- Gilead Sciences Inc
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Biotechnology
- HQ
- 🇺🇸 United States
- Head office
- 333 Lakeside Drive, Foster City, CA, United States, 94404
Leadership & scale
- Chief executive
- Mr. Daniel Patrick O'Day
- CEO year born
- 1965
- Full-time employees
- 17K
- Fiscal year end
- December
- IPO date
- 1992-01-22
Fundamentals snapshot
- Market Cap
- USD 213.8B
- P/E
- --
- Revenue (Q3 26)
- USD 8.3B
- Profit (Q3 26)
- USD 2.4B
- Dividend Yield
- 1.3%
- Revenue (FY 25)
- USD 29.4B
- Shares in public float
- 1.2B
- Insider ownership
- 0.11%
Reporting & identifiers
- Symbol
- GILD.NASDAQ
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US3755581036
- Asset ID
- equity_db3796fa-dbad-5c17-8c00-563cc1f2da1b
Gilead Sciences: Ownership
Shares Outstanding
Latest: 1.3B | Max: 1.3B | Min: 1.3B
Latest reported ownership snapshot
Float Shares
98.94%
1.2B latest reported shares
Insider Ownership
0.11%
Latest reported insider stake
Short Float
0.02%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 1,307,000,000 |
| 2018-01-01 | 1,299,000,000 |
| 2019-01-01 | 1,273,000,000 |
| 2020-01-01 | 1,259,000,000 |
| 2021-01-01 | 1,262,000,000 |
| 2022-01-01 | 1,264,000,000 |
| 2023-01-01 | 1,256,000,000 |
| 2024-01-01 | 1,259,000,000 |
| 2025-01-01 | 1,253,000,000 |
| 2026-01-01 | 1,251,000,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 121,844,108 | 9.82% | 2026-06-30 |
| Vanguard Capital Management, LLC | 81,091,734 | 6.54% | 2026-06-30 |
| FMR Inc | 66,870,816 | 5.39% | 2026-06-30 |
| State Street Corp | 61,216,552 | 4.94% | 2026-06-30 |
| Capital World Investors | 40,988,975 | 3.3% | 2026-06-30 |
| Amvescap Plc. | 39,819,151 | 3.21% | 2026-06-30 |
| Vanguard MStar Total Stk Mkt Idx Invest | 39,372,271 | 3.17% | 2026-09-30 |
| Vanguard Portfolio Management, LLC | 35,316,168 | 2.85% | 2026-06-30 |
| Vanguard 500 Index Investor | 32,565,060 | 2.63% | 2026-09-30 |
| Geode Capital Management, LLC | 30,065,642 | 2.42% | 2026-06-30 |
| T. Rowe Price Associates, Inc. | 29,996,694 | 2.42% | 2026-06-30 |
| Invesco QQQ Trust | 25,793,862 | 2.08% | 2026-10-30 |
| Morgan Stanley - Brokerage Accounts | 24,004,354 | 1.94% | 2026-06-30 |
| Dodge & Cox | 23,677,567 | 1.91% | 2026-06-30 |
| NORGES BANK | 21,965,555 | 1.77% | 2026-06-30 |
Gilead Sciences: Earnings, Profitability & Valuation
Latest Financials Filed On
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Gilead's headline earnings display a dramatic split between accounting figures and operational reality. For the second quarter of 2026, the company reported an eye-catching net loss of over ten billion dollars, yet this paper deficit was driven almost entirely by one-time charges for acquired research. In stark contrast, underlying business performance remained exceptionally strong. Base product revenue climbed ten percent year-over-year, propelled by twelve percent expansion in core HIV medicines and surging prevention demand. Trailing free cash flow exceeded thirteen billion dollars, demonstrating that the underlying cash spigot continues generating robust organic profits.
Gilead's headline earnings display a dramatic split between accounting figures and operational reality. For the second quarter of 2026, the company reported an eye-catching net loss of over ten billion dollars, yet this paper deficit was driven almost entirely by one-time charges for acquired research. In stark contrast, underlying business performance remained exceptionally strong. Base product revenue climbed ten percent year-over-year, propelled by twelve percent expansion in core HIV medicines and surging prevention demand. Trailing free cash flow exceeded thirteen billion dollars, demonstrating that the underlying cash spigot continues generating robust organic profits.
Revenue, Net Income, and Free Cash Flow
Latest: USD 29.4B | Max: USD 30.4B | Min: USD 123.0M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 18x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Gilead commands extraordinary pricing power that keeps underlying profitability among the highest in global healthcare. Gross profit margins consistently hover near seventy-nine percent, sustained by monopolistic antiviral treatments and low manufacturing costs for core tablets. While reported operating margins experienced a temporary paper collapse due to mid-2026 acquisition write-offs, underlying non-GAAP operating margins remain formidable near forty-nine percent. Looking ahead, statutory Medicare price negotiation starting in 2028 will compress net realizations, but rapid adoption of premium preventive formulations should help preserve consolidated operating profitability above forty percent.
Gilead commands extraordinary pricing power that keeps underlying profitability among the highest in global healthcare. Gross profit margins consistently hover near seventy-nine percent, sustained by monopolistic antiviral treatments and low manufacturing costs for core tablets. While reported operating margins experienced a temporary paper collapse due to mid-2026 acquisition write-offs, underlying non-GAAP operating margins remain formidable near forty-nine percent. Looking ahead, statutory Medicare price negotiation starting in 2028 will compress net realizations, but rapid adoption of premium preventive formulations should help preserve consolidated operating profitability above forty percent.
Profitability Margins
Latest: 78.8% | Max: 100.0% | Min: 0.5%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
78.8%
Gross profit / revenue
Operating Margin
39.7%
Operating income / revenue
Net Margin
28.9%
Net income / revenue
FCF Margin
32.1%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 30,390,000,000 | 13,501,000,000 | 16,299,000,000 |
| 2017-12-31 | 26,107,000,000 | 4,628,000,000 | 11,308,000,000 |
| 2018-12-31 | 22,127,000,000 | 5,455,000,000 | 7,476,000,000 |
| 2019-12-31 | 22,449,000,000 | 5,386,000,000 | 8,319,000,000 |
| 2020-12-31 | 24,689,000,000 | 123,000,000 | 7,518,000,000 |
| 2021-12-31 | 27,305,000,000 | 6,225,000,000 | 10,805,000,000 |
| 2022-12-31 | 27,281,000,000 | 4,592,000,000 | 8,344,000,000 |
| 2023-12-31 | 27,116,000,000 | 5,665,000,000 | 7,421,000,000 |
| 2024-12-31 | 28,754,000,000 | 480,000,000 | 10,305,000,000 |
| 2025-12-31 | 29,442,000,000 | 8,510,000,000 | 9,456,000,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 18.1 | Trailing four quarters |
| 2024-12-31 | 242.3 | Trailing four quarters |
| 2023-12-31 | 18 | Trailing four quarters |
| 2022-12-31 | 23.6 | Annual net income |
| 2021-12-31 | 14.7 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 85.98 | 58.02 | 44.43 | 53.63 |
| 2017-12-31 | 83.26 | 54.1 | 17.73 | 43.31 |
| 2018-12-31 | 78.07 | 37.06 | 24.65 | 33.79 |
| 2019-12-31 | 79.18 | 19.1 | 23.99 | 37.06 |
| 2020-12-31 | 81.48 | 16.49 | 0.5 | 30.45 |
| 2021-12-31 | 75.82 | 36.32 | 22.8 | 39.57 |
| 2022-12-31 | 79.26 | 26.87 | 16.83 | 30.59 |
| 2023-12-31 | 100 | 28.05 | 20.89 | 27.37 |
| 2024-12-31 | 78.26 | 5.78 | 1.67 | 35.84 |
| 2025-12-31 | 78.83 | 39.74 | 28.9 | 32.12 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Snapshot retrieved 2026-11-10.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.